Jing Feng

Title: Innovations in Cancer Research by Inventor Jing Feng

Introduction

Jing Feng is a prominent inventor based in Wuhan, China, known for his significant contributions to cancer research. He holds 4 patents that focus on advanced methodologies for predicting tumor mutation burden and improving histopathological image classification. His work is pivotal in enhancing the accuracy of cancer diagnostics, particularly in triple negative breast cancer.

Latest Patents

One of Jing Feng's latest patents is a method and system for predicting tumor mutation burden (TMB) in triple negative breast cancer (TNBC) based on nuclear scores and histopathological whole slide images (WSIs). This innovative approach involves screening histopathological WSIs, calculating TMB values for patients, and utilizing a convolutional neural network (CNN) to predict TMB levels. Another notable patent is an end-to-end attention pooling-based classification method for histopathology images. This method improves classification accuracy for small sample sizes by employing a deep learning network that processes histopathological images in a systematic manner.

Career Highlights

Jing Feng has worked at esteemed institutions such as Wuhan University and the Changjiang River Scientific Research Institute, part of the Changjiang Water Resources Commission. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Throughout his career, Jing Feng has collaborated with notable colleagues, including Juan Liu and Zhiqun Zuo. These partnerships have fostered a collaborative environment that enhances the quality and impact of their research.

Conclusion

Jing Feng's innovative work in cancer research exemplifies the importance of advancements in medical technology. His patents not only contribute to the scientific community but also hold the potential to improve patient outcomes in cancer treatment.